Camp4 Therapeutics Corp. 10-Q Summary: Q3 2025
Business Context and Reporting Period
Camp4 Therapeutics Corp. (CAMP) is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics for genetic diseases. This report covers the quarterly period ended September 30, 2025. The company operates as a single segment focused on research and development (R&D) and is classified as an emerging growth company and smaller reporting company.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|
| Revenue | $0.8 million | $3.2 million | $0 |
| Net Loss | $(15.1) million | $(40.1) million | $(38.5) million |
| Operating Expenses | $14.4 million | $42.9 million | $39.1 million |
| Cash and Cash Equivalents | $75.3 million (as of Sept 30, 2025) | ||
| Working Capital | $69.8 million (as of Sept 30, 2025) | ||
| Accumulated Deficit | $(251.9) million (as of Sept 30, 2025) | ||
| Derivative Tranche Liability | $16.7 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Generation: The company recognized $3.2 million in revenue for the nine months ended September 30, 2025, compared to zero in the prior year. This was driven by a $2.6 million recognition under the BioMarin collaboration and a $0.6 million milestone from Fulcrum Therapeutics.
- Financing Activity: In September 2025, the company completed the initial closing of a private placement, raising net proceeds of $46.7 million. This included the issuance of common stock and pre-funded warrants.
- Derivative Liability Impact: A new derivative tranche liability of $16.7 million was recorded related to the private placement. A $1.8 million loss was recognized in Q3 2025 due to the change in fair value of this liability, driven by an increase in the company's stock price.
- Asset Impairment: The company recognized a $0.5 million impairment charge related to the right-of-use asset for its vacated Boulder, Colorado lease location.
- Expense Trends: R&D expenses decreased slightly in Q3 2025 ($9.4M) compared to Q3 2024 ($9.7M) due to reduced spending on the UCD program. However, G&A expenses increased by $0.8 million in Q3 2025, largely due to professional fees associated with the private placement.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management estimates that cash and cash equivalents of $75.3 million are sufficient to fund operations into 2027. The company expects to continue incurring significant losses as it advances clinical trials.
- Pipeline Strategy:
- CMP-002 (SYNGAP1): The lead candidate for SYNGAP1-related disorders is the primary focus. GLP toxicology studies have been initiated, with a Phase 1/2 clinical trial expected to start in the second half of 2026.
- CMP-001 (UCD): The company has paused new investment in its urea cycle disorder program following a successful Phase 1 trial in healthy volunteers and is actively pursuing partnership opportunities for further development.
- Private Placement Tranche: A second closing of the private placement is contingent on achieving a regulatory milestone and a stock price threshold of $7.50 (or a waiver by investors). If triggered, this could raise up to an additional $50.1 million.
- Risks: Key risks include the need for substantial additional capital, the uncertainty of clinical trial outcomes, reliance on third-party manufacturers, and potential dilution from future equity offerings. The company also faces risks related to international trade policies and tariffs affecting supply chains.
Investor Verification Checklist
- Verify the specific terms and trigger conditions for the second tranche of the September 2025 private placement.
- Confirm the timeline and budget for the upcoming GLP toxicology studies for CMP-002.
- Monitor the status of partnership discussions for the CMP-001 (UCD) program.
- Review the sublease status and potential ongoing costs associated with the vacated Boulder, Colorado facility.
- Assess the impact of the derivative tranche liability on future earnings volatility as stock price fluctuates.